Callan Family Office, LLC Mersana Therapeutics, Inc. Transaction History
Callan Family Office, LLC
- $3.14 Trillion
- Q3 2025
Shares
1 transactions
Others Institutions Holding MRSN
# of Institutions
14Shares Held
22.2MCall Options Held
0Put Options Held
0-
Nextech Invest Ag12.1MShares$331 Million3.22% of portfolio
-
Black Rock Inc. New York, NY8.38MShares$230 Million0.0% of portfolio
-
Decheng Capital Management Iii (Cayman), LLC904KShares$24.8 Million0.64% of portfolio
-
Clari Vest Asset Management LLC San Diego, CA500KShares$13.7 Million0.09% of portfolio
-
Nuveen Asset Management, LLC Chicago, IL232KShares$6.37 Million0.0% of portfolio
About Mersana Therapeutics, Inc.
- Ticker MRSN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,169,296
- Market Cap $2.67B
- Description
- Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...